Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.
